Cargando…
Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
BACKGROUND: Gaining more information about the reciprocal associations between different biomarkers within the ATN (Amyloid/Tau/Neurodegeneration) framework across the Alzheimer’s disease (AD) spectrum is clinically relevant. We aimed to conduct a comprehensive head-to-head comparison of plasma and...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308642/ https://www.ncbi.nlm.nih.gov/pubmed/37381042 http://dx.doi.org/10.1186/s40035-023-00365-x |
_version_ | 1785066288053223424 |
---|---|
author | Lu, Jiaying Ma, Xiaoxi Zhang, Huiwei Xiao, Zhenxu Li, Ming Wu, Jie Ju, Zizhao Chen, Li Zheng, Li Ge, Jingjie Liang, Xiaoniu Bao, Weiqi Wu, Ping Ding, Ding Yen, Tzu-Chen Guan, Yihui Zuo, Chuantao Zhao, Qianhua |
author_facet | Lu, Jiaying Ma, Xiaoxi Zhang, Huiwei Xiao, Zhenxu Li, Ming Wu, Jie Ju, Zizhao Chen, Li Zheng, Li Ge, Jingjie Liang, Xiaoniu Bao, Weiqi Wu, Ping Ding, Ding Yen, Tzu-Chen Guan, Yihui Zuo, Chuantao Zhao, Qianhua |
author_sort | Lu, Jiaying |
collection | PubMed |
description | BACKGROUND: Gaining more information about the reciprocal associations between different biomarkers within the ATN (Amyloid/Tau/Neurodegeneration) framework across the Alzheimer’s disease (AD) spectrum is clinically relevant. We aimed to conduct a comprehensive head-to-head comparison of plasma and positron emission tomography (PET) ATN biomarkers in subjects with cognitive complaints. METHODS: A hospital-based cohort of subjects with cognitive complaints with a concurrent blood draw and ATN PET imaging ((18)F-florbetapir for A, (18)F-Florzolotau for T, and (18)F-fluorodeoxyglucose [(18)F-FDG] for N) was enrolled (n = 137). The β-amyloid (Aβ) status (positive versus negative) and the severity of cognitive impairment served as the main outcome measures for assessing biomarker performances. RESULTS: Plasma phosphorylated tau 181 (p-tau181) level was found to be associated with PET imaging of ATN biomarkers in the entire cohort. Plasma p-tau181 level and PET standardized uptake value ratios of AT biomarkers showed a similarly excellent diagnostic performance for distinguishing between Aβ+ and Aβ− subjects. An increased tau burden and glucose hypometabolism were significantly associated with the severity of cognitive impairment in Aβ+ subjects. Additionally, glucose hypometabolism – along with elevated plasma neurofilament light chain level – was related to more severe cognitive impairment in Aβ− subjects. CONCLUSION: Plasma p-tau181, as well as (18)F-florbetapir and (18)F-Florzolotau PET imaging can be considered as interchangeable biomarkers in the assessment of Aβ status in symptomatic stages of AD. (18)F-Florzolotau and (18)F-FDG PET imaging could serve as biomarkers for the severity of cognitive impairment. Our findings have implications for establishing a roadmap to identifying the most suitable ATN biomarkers for clinical use. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-023-00365-x. |
format | Online Article Text |
id | pubmed-10308642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103086422023-06-30 Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints Lu, Jiaying Ma, Xiaoxi Zhang, Huiwei Xiao, Zhenxu Li, Ming Wu, Jie Ju, Zizhao Chen, Li Zheng, Li Ge, Jingjie Liang, Xiaoniu Bao, Weiqi Wu, Ping Ding, Ding Yen, Tzu-Chen Guan, Yihui Zuo, Chuantao Zhao, Qianhua Transl Neurodegener Research BACKGROUND: Gaining more information about the reciprocal associations between different biomarkers within the ATN (Amyloid/Tau/Neurodegeneration) framework across the Alzheimer’s disease (AD) spectrum is clinically relevant. We aimed to conduct a comprehensive head-to-head comparison of plasma and positron emission tomography (PET) ATN biomarkers in subjects with cognitive complaints. METHODS: A hospital-based cohort of subjects with cognitive complaints with a concurrent blood draw and ATN PET imaging ((18)F-florbetapir for A, (18)F-Florzolotau for T, and (18)F-fluorodeoxyglucose [(18)F-FDG] for N) was enrolled (n = 137). The β-amyloid (Aβ) status (positive versus negative) and the severity of cognitive impairment served as the main outcome measures for assessing biomarker performances. RESULTS: Plasma phosphorylated tau 181 (p-tau181) level was found to be associated with PET imaging of ATN biomarkers in the entire cohort. Plasma p-tau181 level and PET standardized uptake value ratios of AT biomarkers showed a similarly excellent diagnostic performance for distinguishing between Aβ+ and Aβ− subjects. An increased tau burden and glucose hypometabolism were significantly associated with the severity of cognitive impairment in Aβ+ subjects. Additionally, glucose hypometabolism – along with elevated plasma neurofilament light chain level – was related to more severe cognitive impairment in Aβ− subjects. CONCLUSION: Plasma p-tau181, as well as (18)F-florbetapir and (18)F-Florzolotau PET imaging can be considered as interchangeable biomarkers in the assessment of Aβ status in symptomatic stages of AD. (18)F-Florzolotau and (18)F-FDG PET imaging could serve as biomarkers for the severity of cognitive impairment. Our findings have implications for establishing a roadmap to identifying the most suitable ATN biomarkers for clinical use. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-023-00365-x. BioMed Central 2023-06-29 /pmc/articles/PMC10308642/ /pubmed/37381042 http://dx.doi.org/10.1186/s40035-023-00365-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Lu, Jiaying Ma, Xiaoxi Zhang, Huiwei Xiao, Zhenxu Li, Ming Wu, Jie Ju, Zizhao Chen, Li Zheng, Li Ge, Jingjie Liang, Xiaoniu Bao, Weiqi Wu, Ping Ding, Ding Yen, Tzu-Chen Guan, Yihui Zuo, Chuantao Zhao, Qianhua Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints |
title | Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints |
title_full | Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints |
title_fullStr | Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints |
title_full_unstemmed | Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints |
title_short | Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints |
title_sort | head-to-head comparison of plasma and pet imaging atn markers in subjects with cognitive complaints |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308642/ https://www.ncbi.nlm.nih.gov/pubmed/37381042 http://dx.doi.org/10.1186/s40035-023-00365-x |
work_keys_str_mv | AT lujiaying headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT maxiaoxi headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT zhanghuiwei headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT xiaozhenxu headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT liming headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT wujie headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT juzizhao headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT chenli headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT zhengli headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT gejingjie headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT liangxiaoniu headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT baoweiqi headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT wuping headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT dingding headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT yentzuchen headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT guanyihui headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT zuochuantao headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT zhaoqianhua headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints |